

Talia Golan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/449681/publications.pdf>

Version: 2024-02-01

134
papers

8,800
citations

126858

33
h-index

46771

89
g-index

140
all docs

140
docs citations

140
times ranked

12092
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 317-327.	13.9	1,521
2	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. <i>Science</i> , 2020, 368, 973-980.	6.0	1,077
3	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	6.0	1,059
4	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	5.1	943
5	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E1826-34.	3.3	492
6	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
7	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2020, 38, 1378-1388.	0.8	265
8	RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. <i>Oncotarget</i> , 2015, 6, 24560-24570.	0.8	244
9	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	0.6	224
10	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
11	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. <i>Cancer Cell</i> , 2019, 35, 267-282.e7.	7.7	151
12	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4003.	0.8	134
13	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 89, 19-26.	1.3	125
14	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	1.9	91
15	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild-type <i>BRCA</i> pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018, 124, 1374-1382.	2.0	91
16	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVD). <i>European Journal of Cancer</i> , 2020, 137, 272-284.	1.3	86
17	Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2021, 160, 2119-2132.e9.	0.6	83
18	LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 871-879.	2.9	80

#	ARTICLE	IF	CITATIONS
19	Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. <i>European Journal of Cancer</i> , 2019, 120, 122-131.	1.3	76
20	Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 16.	5.8	72
21	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 697-702.	2.9	70
22	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	0.8	66
23	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2617-2631.	0.8	63
24	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 378-378.	0.8	59
25	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline <i>BRCA</i> Variants. <i>JAMA Oncology</i> , 2021, 7, 693.	3.4	56
26	Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3963-3970.	0.7	55
27	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4012-4012.	0.8	55
28	Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1442-1454.	0.8	52
29	Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. <i>Cancer Medicine</i> , 2015, 4, 1472-1483.	1.3	49
30	Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. <i>Cancer</i> , 2013, 119, 3084-3091.	2.0	46
31	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among <i>BRCA1</i> mutation carriers and non-carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 157-165.	1.1	43
32	Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1022-1027.	2.3	42
33	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. <i>Molecular Cancer Research</i> , 2019, 17, 2029-2041.	1.5	37
34	A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3584-3584.	0.8	35
35	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. <i>European Journal of Cancer</i> , 2018, 94, 1-5.	1.3	31
36	ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 817-826.	0.5	31

#	ARTICLE	IF	CITATIONS
37	Phase II study of olaparib for BRCAness phenotype in pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 297-297.	0.8	30
38	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. Journal of Clinical Oncology, 2020, 38, TPS4672-TPS4672.	0.8	29
39	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 1904-1911.	3.2	28
40	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Research, 2019, 79, 4491-4502.	0.4	27
41	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. Nature Cancer, 2022, 3, 219-231.	5.7	24
42	Diffusion Tensor Magnetic Resonance Imaging of the Pancreas. PLoS ONE, 2014, 9, e115783.	1.1	23
43	Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).. Journal of Clinical Oncology, 2019, 37, 2528-2528.	0.8	23
44	Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease. Oncotarget, 2017, 8, 40778-40790.	0.8	23
45	Changing the course of pancreatic cancer â€œ Focus on recent translational advances. Cancer Treatment Reviews, 2016, 44, 17-25.	3.4	21
46	DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1063-1069.	2.3	21
47	Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 9509-9509.	0.8	21
48	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombinationâ€œdeficient Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5462-5476.	3.2	20
49	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. Journal of Clinical Oncology, 2018, 36, 92-92.	0.8	20
50	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Molecular Cancer Therapeutics, 2021, 20, 2166-2176.	1.9	19
51	Recapitulating the clinical scenario of BRCAâ€œassociated pancreatic cancer in preâ€œclinical models. International Journal of Cancer, 2018, 143, 179-183.	2.3	18
52	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2014, 32, 4023-4023.	0.8	17
53	Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. Breast Cancer Research and Treatment, 2016, 155, 133-138.	1.1	15
54	Exclusive destruction of mitotic spindles in human cancer cells. Oncotarget, 2017, 8, 20813-20824.	0.8	15

#	ARTICLE	IF	CITATIONS
55	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g <i>BRCA</i> >). Journal of Clinical Oncology, 2016, 34, TPS4152-TPS4152.	0.8	15
56	Geographic and ethnic heterogeneity in the <i>BRCA1/2</i> pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC). Journal of Clinical Oncology, 2018, 36, 4115-4115.	0.8	15
57	Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology, 2011, 25, 518-26, 529.	0.4	15
58	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Investigational New Drugs, 2020, 38, 1411-1420.	1.2	14
59	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. Journal of Clinical Oncology, 2019, 37, 4009-4009.	0.8	14
60	Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Pharmacoepidemiology and Drug Safety, 2020, 29, 599-604.	0.9	13
61	A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 4037-4037.	0.8	13
62	Patient-derived xenograft models of BRCA-associated pancreatic cancers. Advanced Drug Delivery Reviews, 2021, 171, 257-265.	6.6	12
63	American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. Gastrointestinal Endoscopy, 2022, 95, 827-854.e3.	0.5	12
64	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. Journal of Clinical Oncology, 2019, 37, LBA4-LBA4.	0.8	11
65	Single-Fraction Celiac Plexus Radiosurgery: A Preliminary Proof-of-Concept Phase 2 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 588-593.	0.4	10
66	Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes. Journal of the National Cancer Institute, 2018, 110, 1137-1138.	3.0	8
67	Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. Clinical Colorectal Cancer, 2019, 18, e300-e307.	1.0	8
68	POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.. Journal of Clinical Oncology, 2015, 33, TPS4149-TPS4149.	0.8	8
69	A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.. Journal of Clinical Oncology, 2020, 38, 639-639.	0.8	8
70	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. Clinical Colorectal Cancer, 2019, 18, 226-230.e2.	1.0	7
71	Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review. OncoTargets and Therapy, 2020, Volume 13, 11637-11644.	1.0	7
72	Does pathologic complete response predict for outcome in BRCA mutation carriers with triple-negative breast cancer?. Journal of Clinical Oncology, 2014, 32, 1023-1023.	0.8	7

#	ARTICLE	IF	CITATIONS
73	Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00473.	1.3	7
74	Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	6
75	Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4144-TPS4144.	0.8	6
76	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification—Defining novel predictive and prognostic markers in stage III colon cancer. <i>European Journal of Cancer</i> , 2018, 96, 105-110.	1.3	5
77	Expression of the DNA repair gene <i>MLH1</i> correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. <i>Cancer</i> , 2018, 124, 491-498.	2.0	5
78	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , 2019, 24, e671-e676.	1.9	5
79	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with <i>PARG</i> Inhibition. <i>Molecular Cancer Research</i> , 2021, 19, 565-572.	1.5	5
80	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , 2018, 36, 88-88.	0.8	4
81	The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts. <i>Oncotarget</i> , 2019, 10, 6269-6282.	0.8	4
82	Targeting homologous recombination addicted tumors: challenges and opportunities. <i>Annals of Pancreatic Cancer</i> , 2020, 3, 6-6.	1.2	3
83	Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 278-278.	0.8	3
84	Short and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013.. <i>Journal of Clinical Oncology</i> , 2017, 35, 232-232.	0.8	3
85	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	0.8	3
86	Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 469-473.	2.3	3
87	Phase III study (daNIS-2) of the anti-TGF- β 2 monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4193-TPS4193.	0.8	3
88	Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4023-4023.	0.8	3
89	Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2505-2505.	0.8	3
90	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. <i>Molecular and Clinical Oncology</i> , 2019, 10, 555-559.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 270-270.	0.8	2
92	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2015, 33, 358-358.	0.8	2
93	RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets.. Journal of Clinical Oncology, 2014, 32, e15214-e15214.	0.8	2
94	A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3147-TPS3147.	0.8	2
95	Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, , e333-e343.	1.8	1
96	ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. Annals of Surgical Oncology, 2020, 27, 3971-3972.	0.7	1
97	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. Oncologist, 2021, 26, e111-e114.	1.9	1
98	Mortality Among Neutropenic Cancer Patients Within the United States: The Association With Hospital Volume. JCO Oncology Practice, 2021, 17, OP.20.00115.	1.4	1
99	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2021, 39, 412-412.	0.8	1
100	Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).. Journal of Clinical Oncology, 2021, 39, 420-420.	0.8	1
101	Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. Journal of Clinical Oncology, 2021, 39, e15579-e15579.	0.8	1
102	Abstract CT209: A clinical trial of cResponse, a functional assay for cancer precision medicine. , 2021, , .		1
103	Changing prognosis of metastatic colorectal adenocarcinoma (mCRC) 1988-2008 within the general population: Has everyone benefitted?. Journal of Clinical Oncology, 2012, 30, e14143-e14143.	0.8	1
104	Celiac plexus radiosurgery: A new palliative modality for upper gastrointestinal malignanciesâ€”Final results of a proof-of-concept clinical trial.. Journal of Clinical Oncology, 2018, 36, 10098-10098.	0.8	1
105	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3027-3027.	0.8	1
106	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology, 2018, 36, 276-276.	0.8	1
107	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumorsâ€”Asian subgroup analysis.. Journal of Clinical Oncology, 2018, 36, 723-723.	0.8	1
108	Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomesâ€”Final results of a prospective clinical trial.. Journal of Clinical Oncology, 2019, 37, 309-309.	0.8	1

#	ARTICLE	IF	CITATIONS
109	POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2020, 38, 4626-4626.	0.8	1
110	A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3160-TPS3160.	0.8	1
111	The impact of pancreatic cancer resection in the era of effective systemic treatment.. Journal of Clinical Oncology, 2020, 38, 722-722.	0.8	1
112	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. Journal of Clinical Oncology, 2020, 38, 750-750.	0.8	1
113	Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial. BMJ Open, 2022, 12, e050169.	0.8	1
114	Ascitic derived primary pancreatic cancer cell cultures from different patients as a platform for personalized medicine.. Journal of Clinical Oncology, 2012, 30, e14646-e14646.	0.8	0
115	The role of adjuvant radiation therapy in T4 nonrectal colon cancers.. Journal of Clinical Oncology, 2014, 32, 553-553.	0.8	0
116	Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC).. Journal of Clinical Oncology, 2015, 33, 287-287.	0.8	0
117	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2016, 34, 244-244.	0.8	0
118	Effect of hospital volume on mortality rates amongst neutropenic cancer patients within the United States.. Journal of Clinical Oncology, 2016, 34, 6600-6600.	0.8	0
119	Clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single center.. Journal of Clinical Oncology, 2016, 34, e14549-e14549.	0.8	0
120	ATM as a biomarker for DNA damage repair deficiency in pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 308-308.	0.8	0
121	Integration of Genomic and Transcriptomic Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. SSRN Electronic Journal, 0, , .	0.4	0
122	Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2018, 36, 271-271.	0.8	0
123	A new look at the IDEA classification: Defining novel predictive and prognostic markers in stage III colon cancer.. Journal of Clinical Oncology, 2018, 36, 845-845.	0.8	0
124	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, e15686-e15686.	0.8	0
125	Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.. Journal of Clinical Oncology, 2019, 37, TPS466-TPS466.	0.8	0
126	Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.. Journal of Clinical Oncology, 2019, 37, 636-636.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).. Journal of Clinical Oncology, 2020, 38, 4621-4621.	0.8	0
128	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2020, 38, e16800-e16800.	0.8	0
129	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. Journal of Clinical Oncology, 2020, 38, 686-686.	0.8	0
130	Effect of the botanical compound LCS102 on innate immunity. Biomedical Reports, 2020, 13, 17.	0.9	0
131	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0
132	Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 110-110.	0.8	0
133	Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer. Cancer Research, 2022, 82, CT246-CT246.	0.4	0
134	Abstract 2148: Pre-clinical models recapitulating the spectrum of response of BRCA associated pancreatic cancer. Cancer Research, 2022, 82, 2148-2148.	0.4	0